CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER

CADRENAL THERAPEUTICS

PROVIDES THIRD-QUARTER CORPORATE UPDATE

PONTE VEDRA, Fla., Nov.

7, 2024 - Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) (the "Company" or "Cadrenal"), a late-stage biopharmaceutical

company developing tecarfarin, a new vitamin K antagonist (VKA) designed to provide safer and superior anticoagulation for patients with

implanted cardiac devices or rare cardiovascular conditions, today provided a corporate update coinciding with the filing of its Quarterly

Report on Form 10-Q for the quarter ended September 30, 2024.

"Momentum is building

from our achievement of several critical milestones toward beginning a pivotal clinical trial to evaluate tecarfarin's superiority

to warfarin in LVAD patients," said Quang X. Pham, Founder, Chairman, and Chief Executive Officer of Cadrenal Therapeutics. "These

accomplishments span finance, operations, partner relations, and clinical development and enhance our ability to execute our strategic

plan going into 2025.

"Efficiently raising

nearly $10 million in recent weeks bolsters funds for operational and clinical development needs. At the same time, we are progressing

our dialogue with the FDA and Abbott and moving ahead with our CDMO to manufacture tecarfarin for our Phase 3 trial," continued

Tecarfarin is the only

anticoagulant in development worldwide for patients with implanted cardiac devices and other rare cardiovascular conditions. The oral

and reversible drug has been uniquely designed to overcome many of the challenges patients experience with warfarin and to fill a need

unmet by direct oral anticoagulants (DOACs) that are contraindicated or not recommended by leading cardiology associations for these individuals.

If approved, tecarfarin may be a safer and more effective chronic anticoagulant for LVAD patients in the U.S.

In addition, tecarfarin

may prove valuable for other patients where warfarin is not providing recommended anticoagulation because of genetic warfarin resistance

or renal impairment making warfarin metabolism difficult. These include individuals with end-stage renal disease and atrial fibrillation

or those with mechanical heart valves and hard-to-control anticoagulation, as determined by International Normalized Ratio (INR) measurements

of how long it takes the blood to clot.

ABOUT CADRENAL THERAPEUTICS,

Therapeutics is a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to offer safer,

more effective chronic anticoagulation for patients with implanted cardiac devices or rare cardiovascular conditions. Tecarfarin is anticipated

to result in fewer adverse events such as strokes, heart attacks, bleeds, and deaths than warfarin, the most commonly used anticoagulant

for these patients, despite its prevalent adverse events, drug-to-drug interactions, and frequent dosing changes. Cadrenal is focused

on evaluating tecarfarin's superiority to warfarin in these patients where DOACs are not recommended in the treatment guidelines

of leading cardiology associations. Tecarfarin received an orphan drug designation for advanced heart failure patients with implanted

LVADs as well as both orphan drug and fast-track status for end-stage kidney disease patients with atrial fibrillation. Cadrenal is opportunistically

planning pivotal clinical trials and pursuing clinical and commercial partnerships to advance tecarfarin. The company's plans also

include studying tecarfarin in patients with mechanical heart valves experiencing anticoagulation difficulties. Visit www.cadrenal.com to

is a Phase 3-ready drug candidate that Cadrenal is developing to overcome many of warfarin's challenges and fill the need for a

safer and more effective VKA chronic anticoagulant. Tecarfarin is anticipated to improve outcomes and result in fewer major events for

warfarin-dependent patients. Extensive data indicates that the efficacy of tecarfarin, metabolized via a different pathway than warfarin,

is not affected by drug-drug interactions and kidney impairment , which are common in these patients. Phase 2/3 clinical trials show that

tecarfarin may offer enhanced stability and time in therapeutic range (TTR) that inversely correlate with major events. Tecarfarin is

the only new anticoagulant being developed for patients with implanted cardiac devices or rare cardiovascular conditions. Treatment with

tecarfarin aims to improve anticoagulation for these underserved patients and their healthcare providers who face difficulties in managing

warfarin's wide variability and risk of gastrointestinal bleeds.

Safe Harbor Statement

Any statements contained

in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not

historical facts, may constitute "forward-looking statements." These statements include statements regarding our planned pivotal

trial to evaluate tecarfarin's effectiveness for LVAD patients, the success of the Company's collaborative efforts with Abbott,

tecarfarin potentially being a safer and more effective chronic anticoagulant for patients with LVADs, tecarfarin filling a need unmet

by DOACs that are contraindicated or not recommended, the commencement of trials to evaluate tecarfarin's superiority to warfarin

in LVAD patients and potentially bring the Company's better anticoagulation solution to those in need, and tecarfarin proving valuable

for other patients where warfarin is not providing recommended anticoagulation because of genetic warfarin resistance or renal impairment

making warfarin metabolism difficult. The words "anticipate," "believe," "continue," "could,"

"estimate," "expect," "intend," "may," "plan," "potential," "predict,"

"project," "should," "target," "will," "would" and similar expressions are

intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results

may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the

ability of tecarfarin to improve anticoagulation treatment in patients, the ability of the Company to advance tecarfarin with patients

with left ventricular assist devices (LVADs), the collaborative efforts with Abbott being successful and those with AFib and ESKD,

the collaboration with Abbott being successful and the other risk factors described in the Company's Annual Report on Form 10-K

for the year ended December 31, 2023, and the Company's subsequent filings with the Securities and Exchange Commission, including

subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained

in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims

any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information,

Cadrenal Therapeutics:

Lytham Partners, LLC

Robert Blum, Managing Partner